The Economics of Healthcare: Balancing Social Values with Free Markets
Capitalism works. In competitive markets, it drives efficiency, encourages innovation, offers consumers greater choice, and allows prices to respond to supply and demand. The incentives created by competition and the pursuit of profit have contributed substantially to economic growth, technological progress, and improvements in living standards. However, the efficiency of capitalism must be balanced with the values of society, particularly where market outcomes conflict with widely accepted social objectives.
Values are a set of general principles. They are neither universal nor immutable, and there will always be disagreements about their relative importance and practical application. Nevertheless, public policy in a democratic society is generally based on some degree of consensus concerning these principles. Most advanced democracies have developed institutions and policies intended to ensure certain basic conditions of welfare, including:
- Access to healthcare
- Safety and personal security
- Protection from external enemies
- Access to basic education
- Access to adequate housing
There are many approaches to addressing these objectives, ranging from social welfare programs based on a universal basic income or negative income tax to more structured arrangements in which public authorities finance or directly provide services. Hybrid approaches combine elements of competitive markets with public financing, regulation, and redistribution. The appropriate institutional arrangement depends on the characteristics of the service being provided, the economic incentives involved, and the priorities of society.
Certain institutions are particularly difficult to provide effectively through ordinary private markets, including the police, courts, national defence, and environmental protections such as safe drinking water and clean air. The economic reasons vary. National defence has the characteristics of a public good, environmental pollution creates negative externalities, and the administration of justice requires impartiality and legitimate public authority. In each case, the market mechanism has limitations that justify some form of collective provision or intervention.
Healthcare presents a related, although more complicated, economic problem.
Healthcare and Market Failures
Healthcare exhibits several characteristics that distinguish it from ordinary consumer markets. These include supply constraints, relatively inelastic demand for essential and emergency treatment, substantial information asymmetries, barriers to entry, insurance-market failures, and externalities associated with public health.
An externality occurs when an economic activity imposes costs or confers benefits on people who are not directly involved in the transaction, and those effects are not adequately reflected in market prices. Healthcare produces significant positive externalities, particularly in the prevention and control of infectious diseases. Vaccination, early diagnosis, and treatment can benefit individuals while reducing the probability that others will become infected. The social benefits of these interventions may therefore exceed the benefits received by the individual patient.
The prevention of measles, influenza, tuberculosis, and COVID-19 illustrates this problem. Decisions concerning vaccination, testing, and treatment affect disease transmission throughout the population. Consequently, leaving these decisions entirely to individual willingness or ability to pay can result in less preventive healthcare than would be socially desirable.
Healthcare also exhibits substantial information asymmetry. Patients generally lack the expertise necessary to assess the appropriateness, quality, or safety of medical treatment. They depend on physicians, pharmaceutical manufacturers, hospitals, and regulatory authorities to ensure that treatments meet acceptable standards.
Demand presents another difficulty. When someone suffers a stroke, heart attack, or serious accident, that person is rarely in a position to compare hospitals, negotiate with ambulance services, or select physicians according to price and quality. Demand for emergency treatment is highly price-inelastic, while decisions must often be made under considerable uncertainty. Even in non-emergency situations, patients may have difficulty evaluating whether a proposed procedure is medically necessary or whether an alternative treatment would produce comparable results.
Insurance introduces additional complications. Individuals differ in their expected healthcare costs, and insurers may have incomplete information about these risks. Without appropriate regulation or risk-sharing arrangements, insurers have incentives to avoid expensive patients or charge premiums that make coverage unaffordable to people who need it most. Adverse selection can also undermine insurance pools when healthier individuals decline coverage, leaving a progressively more expensive population to insure.
These problems were examined in Kenneth Arrow's influential 1963 paper, Uncertainty and the Welfare Economics of Medical Care, which identified the importance of uncertainty and the institutional characteristics that distinguish healthcare from conventional competitive markets.
The objective of providing healthcare access to everyone introduces a further constraint. Access must extend to people whose medical needs exceed their capacity to pay, including those with chronic illnesses, disabilities, or conditions requiring expensive treatments. Achieving universal access therefore requires financing arrangements that distribute costs across individuals and over time.
Supply Constraints and the Cost of Regulation
The supply of healthcare is constrained by the production of pharmaceuticals, the number of graduates from medical schools, the availability of qualified personnel, medical equipment, hospital capacity, and numerous other factors. These constraints are especially important because supply cannot respond immediately to increases in demand or prices.
Some constraints are technological or physical, while others arise from professional standards and regulation. Many are necessary to protect patients, although their economic consequences must still be considered.
Developing a new pharmaceutical product requires extensive research, clinical trials, safety evaluations, manufacturing controls, and regulatory approval. The associated costs can be substantial. A 2025 study published in JAMA Network Open, examining 38 drugs approved by the FDA in 2019, estimated median research and development costs of $708 million and mean costs of $1.31 billion per approved drug, including adjustments for unsuccessful development and the cost of capital. Broader estimates have reached approximately $2 billion or more, although the results depend heavily on methodology, therapeutic area, and which costs are included.
The training of physicians presents similar barriers. According to the Association of American Medical Colleges, becoming a physician in the United States typically requires between 11 and 16 years of education and training, including undergraduate studies, medical school, and residency. Additional fellowship training may extend this period.
Medical equipment must also meet rigorous safety and performance standards. CT scanners, X-ray systems, radiotherapy equipment, and other technologies can cause serious harm if they are improperly designed, manufactured, maintained, or operated.
Even with established safety procedures and regulatory oversight, accidents occur. During the 1980s, the Therac-25 radiation treatment system was involved in six known incidents of massive radiation overdoses, resulting in deaths and serious injuries. The accidents exposed serious deficiencies in software engineering and system safety. A more recent example occurred at Cedars-Sinai Medical Center between 2008 and 2009, when hundreds of patients undergoing CT brain perfusion scans received excessive radiation doses because of improperly configured scanning protocols.
These cases illustrate why safety standards, professional qualifications, testing, and regulatory supervision are necessary. Patients cannot reasonably be expected to independently establish the safety of medical equipment or the competence of the professionals treating them.
The conventional market response to constrained supply is that higher prices attract additional suppliers. This mechanism certainly operates in healthcare, but its effectiveness is limited by substantial barriers to entry and the time required to expand capacity. Higher physician salaries cannot immediately produce additional qualified physicians or additional medical schools. Similarly, higher pharmaceutical prices cannot eliminate the scientific uncertainties, development costs, or clinical testing requirements associated with introducing new medications.
These considerations help explain why no advanced economy, including the United States, operates an entirely unregulated healthcare market.
The Problem of Universal Access
The economic difficulties become particularly apparent when a society adopts universal healthcare access as a policy objective.
Universal access requires some mechanism for providing treatment independently of an individual's immediate ability to pay. Competitive markets allocate scarce goods and services through prices, and the distribution of purchasing power consequently influences who receives treatment. Where patients cannot afford the market price, access may be delayed, reduced, or unavailable.
This problem is observable in the United States. According to the OECD's Health at a Glance 2025, American healthcare spending amounted to approximately 17.2% of GDP in 2024, compared with an OECD average of 9.3%. Despite this level of expenditure, the United States has not achieved universal insurance coverage.
The U.S. Census Bureau reported that 26.7 million Americans, approximately 7.9% of the population, were uninsured throughout 2025. Insurance coverage also does not necessarily guarantee affordable access to treatment. A 2026 Commonwealth Fund survey found that 30% of working-age adults who had been insured continuously during the preceding year were underinsured, meaning that their deductibles or out-of-pocket costs were high relative to their incomes.
The financial implications are substantial. In its 2025 report on household economic well-being, the Federal Reserve found that 28% of American adults had forgone some form of medical treatment because of cost during 2024. Among adults with household incomes below $25,000, the figure was 41%.
These findings demonstrate that a healthcare system can offer advanced medical technology and high-quality treatment while leaving significant parts of the population exposed to financial barriers. High expenditure alone is insufficient to ensure universal access, affordability, or efficient resource allocation.
International evidence reinforces the importance of financial protection. The WHO and World Bank's 2025 Universal Health Coverage report estimated that 2.1 billion people experienced financial hardship associated with out-of-pocket healthcare expenditure in 2022.
A healthcare system must therefore address three interconnected objectives: cost, quality, and access. Optimizing one without considering the others can produce undesirable outcomes. Limiting expenditure may restrict treatment availability, expanding access without increasing capacity may lengthen waiting times, and improving the availability of advanced treatments may increase total costs.
There is no single institutional arrangement that automatically resolves these trade-offs.
Different Approaches to Healthcare Provision
Advanced economies have adopted a variety of systems, ranging from predominantly tax-funded public provision, as in the United Kingdom, to national insurance arrangements involving private providers, nonprofit insurers, and regulated competition.
Each approach has advantages and disadvantages. The experiences of Singapore, Switzerland, the Nordic countries, and the Netherlands provide useful comparisons.
Singapore: Cost Efficiency
Singapore combines mandatory health savings accounts, government subsidies, and catastrophic health insurance. Its system is designed to provide broad access while maintaining incentives for cost-conscious consumption and efficient resource allocation.
The principal financing mechanisms are MediSave, a compulsory medical savings program; MediShield Life, which provides lifelong basic insurance against large medical expenses for citizens and permanent residents; and MediFund, which assists people unable to pay their medical bills after other forms of support have been exhausted.
Singapore achieves strong health outcomes with relatively modest expenditure. According to the Commonwealth Fund's 2026 country profile, healthcare expenditure amounted to approximately 4.9% of GDP in 2022, while life expectancy was approximately 83.5 years in the more recent data reported in the profile. In 2022, government spending accounted for approximately 57% of total healthcare expenditure.
The principal strengths are comparatively low expenditure, a combination of public and private provision, and generally good health outcomes. Its financing structure also attempts to preserve individual incentives to consider the costs of treatment.
The principal weaknesses include relatively substantial out-of-pocket expenditure, limitations in financial protection for some patients, and disparities affecting migrant workers and other nonresidents. Singapore's success also depends on extensive public regulation, subsidies, and institutional arrangements that are not necessarily transferable to larger countries.
Switzerland: Access and Quality
Switzerland operates a universal healthcare system based on compulsory, regulated health insurance. Residents are required to purchase basic coverage from approved nonprofit insurers, which must accept applicants regardless of their health status. Government subsidies assist lower-income households with insurance premiums.
The Swiss system preserves considerable patient choice and private participation while requiring insurers to provide a standardized package of essential benefits. Competition operates within a regulatory framework designed to prevent exclusion based on medical risk.
Its principal strengths are universal mandatory coverage, high-quality medical services, substantial patient choice, and comparatively good access to treatment.
Its principal weaknesses are cost and financial burden. Switzerland spent approximately 11.8% of GDP on healthcare in 2024, according to the OECD. Insurance premiums, deductibles, and other patient contributions can be substantial, despite public subsidies. The system also involves considerable administrative and regulatory complexity.
Switzerland demonstrates that universal coverage and competition among private insurers can coexist, although the resulting system may remain expensive.
Nordic Systems: Universal Access and Public Financing
Sweden, Denmark, and Norway operate predominantly tax-funded healthcare systems with extensive public involvement in financing, administration, and service provision. These systems emphasize universal access, primary care, and the distribution of healthcare costs across the population.
Their healthcare expenditures are substantial but generally below those of the United States. OECD figures for 2024 place spending at approximately 11.3% of GDP in Sweden, 9.4% in Denmark, and 9.7% in Norway.
Their principal strengths include universal coverage, relatively strong financial protection, and good population health outcomes. Financing through taxation reduces the relationship between a patient's immediate purchasing power and access to essential treatment.
Their principal weaknesses include relatively high taxation and waiting times for some specialist consultations and non-urgent procedures. Although these problems vary across countries and medical specialties, they illustrate the difficulties associated with allocating limited medical resources without relying primarily on prices.
The OECD's 2025 analysis of waiting times found considerable variation across countries and procedures. For example, Sweden's median waiting time for hip replacement surgery was 67 days in 2024. Such figures should be interpreted alongside measures of urgency, clinical outcomes, and affordability.
Netherlands: A Regulated Hybrid Model
The Netherlands combines universal insurance coverage with competition among private insurers and predominantly private healthcare providers. Everyone who lives or works in the country is generally required to obtain basic health insurance, and insurers must accept applicants for the standard package without varying premiums according to individual health status.
The government determines the essential benefits package, provides financial assistance to eligible lower-income households, and operates risk-equalization arrangements intended to compensate insurers for differences in the expected healthcare costs of their members.
Its principal strengths include universal coverage, patient choice, generally high-quality treatment, and a structure that preserves competition among insurers and providers. In the Commonwealth Fund's 2024 comparison of ten advanced healthcare systems, the Netherlands ranked among the strongest performers in access to care.
Its principal weaknesses include administrative complexity, mandatory deductibles, and relatively high overall expenditure. Healthcare spending amounted to approximately 10.1% of GDP in 2024, according to OECD data.
The Dutch experience suggests that competition can contribute to the provision of universal healthcare when supported by compulsory participation, standardized benefits, subsidies, and risk sharing.
Balancing Economic Efficiency and Social Objectives
The experiences of these countries demonstrate that universal healthcare does not require the elimination of private enterprise. Private hospitals, physicians, insurers, pharmaceutical manufacturers, and medical technology companies can operate within systems that guarantee broad access and distribute financial risks across society.
Indeed, competitive incentives can contribute to innovation, operational efficiency, and improvements in quality. However, the existence of private providers or insurers does not eliminate the economic problems associated with uncertainty, information asymmetry, externalities, and unequal purchasing power.
A purely market-financed healthcare system has no inherent mechanism for guaranteeing access to individuals who cannot afford treatment. If universal healthcare is a social objective, additional arrangements are required, whether through taxation, compulsory insurance, subsidies, risk pooling, direct public provision, or combinations of these approaches.
The question then becomes which arrangements achieve the best balance among cost, quality, and access while preserving incentives for innovation and efficiency.
No system is free from trade-offs. Public provision can introduce bureaucratic inefficiencies and capacity constraints. Regulated private insurance can produce administrative complexity and substantial premiums. Health savings accounts can encourage cost-conscious decisions but may provide insufficient protection against expensive illnesses without complementary insurance and subsidies.
There are also important distinctions between the sources of healthcare expenditure. Some costs arise from legitimate improvements in treatment quality, medical technology, and population longevity. Others reflect administrative inefficiency, market concentration, poorly designed incentives, or regulation that imposes costs disproportionate to its benefits. Effective policy must distinguish between them.
Ultimately, healthcare policy is inseparable from social values. If a society believes that every person should have access to essential medical treatment, its healthcare institutions must incorporate mechanisms that make such access possible. Markets can remain central to the delivery of services, but the financing and regulatory framework must reflect that collective objective.
The alternative is a system in which access depends more heavily on individual purchasing power. Such a system may preserve considerable freedom of choice for those who can afford treatment, but it also entails accepting greater risks of untreated illness, delayed diagnosis, avoidable transmission of infectious diseases, and financial hardship and even ruin from serious medical conditions, including cancer.
Capitalism remains an effective mechanism for allocating resources, encouraging innovation, and responding to consumer preferences. Its effectiveness, however, depends on the characteristics of the market in which it operates. Healthcare is an area where the ordinary assumptions of competitive markets are frequently violated, and where the consequences of exclusion extend beyond individual consumers.
A successful healthcare system must therefore reconcile economic efficiency with the social objectives it is intended to serve. The available international evidence suggests that this can be accomplished through several institutional arrangements, provided that universal access, financial protection, safety, and incentives for efficient delivery are incorporated into the system's design.